Core Viewpoint - Wohuah Pharmaceutical's stock has shown a significant increase of 42.06% year-to-date, with a recent price of 6.62 CNY per share, indicating strong market interest and performance [1][2]. Company Overview - Wohuah Pharmaceutical, established on February 9, 2002, and listed on January 24, 2007, specializes in the research, production, and sales of natural plant-based cardiovascular traditional Chinese medicine [1]. - The company's revenue composition includes 69.17% from cardiovascular drugs, 23.46% from musculoskeletal drugs, 3.59% from other categories, 2.97% from antiviral respiratory drugs, and 0.81% from reproductive and urinary system drugs [1]. Financial Performance - For the period from January to September 2025, Wohuah Pharmaceutical reported a revenue of 625 million CNY, reflecting a year-on-year growth of 8.31%, and a net profit attributable to shareholders of 63.995 million CNY, which is a substantial increase of 179.34% year-on-year [2]. - The company has distributed a total of 692 million CNY in dividends since its A-share listing, with 214 million CNY distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Wohuah Pharmaceutical had 41,000 shareholders, an increase of 17.18% from the previous period, with an average of 13,892 circulating shares per shareholder, down by 14.66% [2]. - Notable new institutional shareholders include Baodao Jiuhang Mixed A and Guotai Haitong CSI 500 Index Enhanced A, which are now among the top ten circulating shareholders [3].

Core Insights - Wohuah Pharmaceutical's stock price increased by 2.13% on October 31, reaching 6.22 CNY per share, with a total market capitalization of 3.59 billion CNY [1] - The company has seen a year-to-date stock price increase of 33.48%, but has experienced a slight decline of 0.32% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Wohuah Pharmaceutical reported a revenue of 625 million CNY, representing a year-on-year growth of 8.31% [2] - The net profit attributable to shareholders for the same period was 63.995 million CNY, showing a significant year-on-year increase of 179.34% [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 41,000, up by 17.18% from the previous period [2] - The average number of circulating shares per shareholder decreased by 14.66% to 13,892 shares [2] Dividend Distribution - Since its A-share listing, Wohuah Pharmaceutical has distributed a total of 692 million CNY in dividends, with 214 million CNY distributed over the last three years [3] Institutional Holdings - As of September 30, 2025, notable new institutional shareholders include Baodao Jiuhang Mixed A and Guotai Haitong CSI 500 Index Enhanced A, holding 998,900 shares and 931,200 shares respectively [3]